1. Hirakata, H.; Hatano, Y.; Ushikubi, F.; Mori, K.; Narumiya, S.; Nakamura, K. The Effect of Inhaled Anesthetics on the Platelet Aggregation and the Ligand-Binding Affinity of the Platelet Thromboxane A2 Receptor. Anesth. Analg. 1995, 81, 114–118. [PubMed]
2. Hirakata, H.; Ushikubi, F.; Toda, H.; Nakamura, K.; Sai, S.; Urabe, N.; Hatano, Y.; Narumiya, S.; Mori, K. Sevoflurane inhibits human platelet aggregation and thromboxane A 2 formation, possibly by suppression of cyclooxygenase activity. Anesthesiology 1996, 85, 1447–1453. [CrossRef] [PubMed]
3. Hirakata, H.; Nakamura, K.; Sai, S.; Okuda, H.; Hatano, Y.; Urabe, N.; Mori, K. Platelet aggregation is impaired during anaesthesia with sevoflurane but not with isoflurane. Can. J. Anaesth. 1997, 44, 1157–1161. [CrossRef] [PubMed]
4. Hirakata, H.; Nakamura, K.; Yokubol, B.; Toda, H.; Hatano, Y.; Urabe, N.; Mori, K. Propofol Has Both Enhancing and Suppressing Eflects on Human Platelet Aggregation. Anesthesiology 1999, 91, 1361–1369. [CrossRef] [PubMed]
5. Nakagawa, T.; Hirakata, H.; Sato, M.; Nakamura, K.; Hatano, Y.; Nakamura, T.; Fukuda, K. Ketamine suppresses platelet aggregation possibly by suppressed inositol triphosphate formation and subsequent suppression of cytosolic calcium increase. Anesthesiology 2002, 96, 1147–1152. [CrossRef]
6. Kawamoto, S.; Hirakata, H.; Sugita, N.; Fukuda, K. Bidirectional effects of dexmedetomidine on human platelet functions in vitro. Eur. J. Pharmacol. 2015, 766, 122–128. [CrossRef] [PubMed]
7. Kawamoto, S.; Fukuda, K. Dexmedetomidine increases human platelet-derived microparticles via the α2-adrenoceptor. J. Jpn. Soc. Intensive Care Med. 2018, 25, 457–459. [CrossRef]
8. Hunter, J.M. Rocuronium: The newest aminosteroid neuromuscular blocking drug. Br. J. Anaesth. 1996, 76, 481–483. [CrossRef]
9. Braga, S.S. Cyclodextrins: Emerging Medicines of the New Millennium. Biomolecules 2019, 9, 801. [CrossRef]
10. Welliver, M.; McDonough, J.; Kalynych, N.; Redfern, R. Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent. Drug Des. Dev. Ther. 2008, 2, 49–59. [CrossRef]
11. Kahner, B.N.; Shankar, H.; Murugappan, S.; Prasad, G.L.; Kunapuli, S.P. Nucleotide receptor signaling in platelets. J. Thromb. Haemost. 2006, 4, 2317–2326. [CrossRef] [PubMed]
12. Gachet, C. P2 receptors, platelet function and pharmacological implications. Thromb. Haemost. 2008, 99, 466–472. [CrossRef] [PubMed]
13. Keularts, I.M.L.W.; van Gorp, R.M.A.; Feijge, M.A.H.; Vuist, W.M.J.; Heemskerk, J.W.M. α 2A-Adrenergic Receptor Stimulation Potentiates Calcium Release in Platelets by Modulating cAMP Levels. J. Biol. Chem. 2000, 275, 1763–1772. [CrossRef] [PubMed]
14. Pabinger, I.; Thaler, J.; Ay, C. Biomarkers for prediction of venous thromboembolism in cancer. Blood 2013, 122, 2011–2019. [CrossRef] [PubMed]
15. Merten, M.; Thiagarajan, P. P-Selectin Expression on Platelets Determines Size and Stability of Platelet Aggregates. Circulation 2000, 102, 1931–1936. [CrossRef]
16. Christersson, C.; Johnell, M.; Siegbahn, A. Tissue factor and IL8 production by P-selectin-dependent platelet-monocyte aggregates in whole blood involves phosphorylation of Lyn and is inhibited by IL10. J. Thromb. Haemost. 2008, 6, 986–994. [CrossRef]
17. Yokoyama, S.; Ikeda, H.; Haramaki, N.; Yasukawa, H.; Murohara, T.; Imaizumi, T. Platelet P-selectin plays an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates. J. Am. Coll. Cardiol. 2005, 45, 1280–1286. [CrossRef]
18. Naim, M.J.; Alam, O.; Alam, M.J.; Alam, P.; Shrivastava, N. A review on pharmacological profile of Morpholine derivatives. Int. J. Pharmacol. Pharm. Sci. 2015, 3, 40–51.
19. Wang, X.M.; Xin, M.H.; Xu, J.; Kang, B.R.; Li, Y.; Lu, S.M.; Zhang, S.Q. Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in vitro and in vivo. Eur. J. Med. Chem. 2015, 96, 382–395. [CrossRef]
20. Senwar, K.R.; Sharma, P.; Reddy, T.S.; Jeengar, M.K.; Nayak, V.L.; Naidu, V.G.M.; Kamal, A.; Shankaraiah, N. Spirooxindole-derived morpholine-fused-1,2,3-triazoles: Design, synthesis, cytotoxicity and apoptosis inducing studies. Eur. J. Med. Chem. 2015, 102, 413–424. [CrossRef]
21. Smelcerovic, A.; Rangelov, M.; Smelcerovic, Z.; Veljkovic, A.; Cherneva, E.; Yancheva, D.; Nikolic, G.M.; Petronijevic, Z.; Kocic, G. Two 6-(propan-2-yl)-4-methyl-morpholine-2,5-diones as new non-purine xanthine oxidase inhibitors and anti-inflammatory agents. Food Chem. Toxicol. 2013, 55, 493–497. [CrossRef] [PubMed]
22. Khanum, S.A.; Begum, B.A.; Girish, V.; Khanum, N.F. Synthesis and evaluation of benzophenone-n-ethyl morpholine ethers as anti-inflammatory agents. Int. J. Biomed. Sci. 2010, 6, 60–65.
23. Kuettel, S.; Zambon, A.; Kaiser, M.; Brun, R.; Scapozza, L.; Perozzo, R. Synthesis and evaluation of antiparasitic activities of new 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine derivatives. J. Med. Chem. 2007, 50, 5833–5839. [CrossRef]
24. Ahn, Y.H.; Lee, J.Y.; Park, H.D.; Kim, T.H.; Park, M.C.; Choi, G.; Kim, S. Identification of a new morpholine scaffold as a P2Y12 receptor antagonist. Molecules 2016, 21, 1114. [CrossRef] [PubMed]
25. Suzuki, T.; Saeki, S.; Takeda, J.; Ozaki, M.; Iwao, Y. Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients. Masui 2006, 55, 419–427. [PubMed]
26. Bevan, D.R. Rocuronium bromide and organ function. Eur. J. Anaesthesiol. Suppl. 1994, 9, 87–91.
27. Magorian, T.; Wood, P.; Caldwell, J.; Fisher, D.; Segredo, V.; Szenohradszky, J.; Sharma, M.; Gruenke, L.; Miller, R. The Pharmacokinetics and Neuromuscular Effects of Rocuronium Bromide in Patients with Liver Disease. Anesth. Analg. 1995, 80, 754–759.
28. Szenohradszky, J.; Fisher, D.M.; Segredo, V.; Caldwell, J.E.; Bragg, P.; Sharma, M.L.; Gruenke, L.D.; Miller, R.D. Pharmacokinetics of Rocuronium Bromide (ORG 9426) in Patients with Normal Renal Function or Patients Undergoing Cadaver Renal Transplantation. Anesthesiology 1992, 77, 899–904. [CrossRef]
29. Matteo, R.S.; Ornstein, E.; Schwartz, A.E.; Ostapkovich, N.; Stone, J.G. Pharmacokinetics and Pharmacodynamics of Rocuronium (Org 9426) in Elderly Surgical Patients. Anesth. Analg. 1993, 77, 1193–1197. [CrossRef]
30. Jacob, S.; Nair, A.B. Cyclodextrin complexes: Perspective from drug delivery and formulation. Drug Dev. Res. 2018, 79, 201–217. [CrossRef]
31. Clarke, R.C.; Sadleir, P.H.M.; Platt, P.R. The role of sugammadex in the development and modification of an allergic response to rocuronium: Evidence from a cutaneous model. Anaesthesia 2012, 67, 266–273. [CrossRef] [PubMed]
32. Limbird, L.E. Receptors linked to inhibition of adenylate cyclase: Additional signaling mechanisms. FASEB J. 1988, 2, 2686–2695. [CrossRef] [PubMed]